Genmab A/S (GMAB) Stock Forecast & Price Target

GMAB$51.37—
BiotechnologyLarge CapHigh Quality
Compare
Market cap$31.20BEnterprise value—Revenue (TTM)$4.3BMarket positionTop 25%

Score

37
Bearish
Value
29
Quality
63
Growth
20

Genmab A/S price target

GMAB
Low$32.00
Median$42.50
High$70.00
Upside vs current price-17.3%

The median target of $42.50 is -17.3% versus the current GMAB price of $51.37.

Genmab A/S analyst ratings

RatingAnalysts
Strong buy1
Buy10
Hold2
Sell0
Strong sell0
ConsensusBuy

13 analysts cover GMAB.

Genmab A/S EPS and revenue estimates

GMAB shows the next fiscal years with at least three analysts: 2026 EPS $1.25, 2027 EPS $1.63. A thinner year is left off this table.

Fiscal yearEPS estimateRevenue estimate
2026$1.25$4.47B
2027$1.63$5.41B

Is Genmab A/S a buy or sell?

Of the 13 analysts covering Genmab A/S, 11 rate it a buy (1 strong buy and 10 buy), 2 rate it a hold, and 0 rate it a sell (0 sell and 0 strong sell).

The GMAB consensus label is Buy, beside 11 buy-side ratings and 0 sell-side ratings.

The median target of $42.50 implies -17.3% versus the current price of $51.37.

Those 13 ratings on GMAB are a headcount, and the label on file is Buy.

Reading the Genmab A/S forecast

The GMAB target range is wide: $32.00 at the low end, $42.50 in the middle, and $70.00 at the top.

Set next to the $51.37 GMAB quote, that median is -17.3%.

Ratings on the Genmab A/S cluster: 11 of 13 analysts are on the buy side, 2 are at hold, and 0 are on the sell side, and the published consensus is Buy.

Recent GMAB revisions are two-sided: 1 upgrades and 0 downgrades.

The average GMAB target over the last month is $61.00, above the $55.50 average of the last quarter.

Only 8 desks have a fresh median target on GMAB, so the range rests on a short list.

Genmab A/S forecast questions

What is the GMAB price target?

The published range for GMAB is $32.00 to $70.00, with a median target of $42.50. That median is -17.3% versus the current price of $51.37.

Is Genmab A/S a buy or sell?

Of the 13 analysts covering Genmab A/S, 11 rate it a buy, 2 rate it a hold, and 0 rate it a sell. The consensus is Buy, and the GMAB headcount is 11 buy, 2 hold, and 0 sell.

What is the EPS estimate for Genmab A/S?

Analyst EPS estimates for Genmab A/S: 2026 $1.25, 2027 $1.63.

What is the revenue estimate for Genmab A/S?

Analyst revenue estimates for Genmab A/S: 2026 $4.47B, 2027 $5.41B.

How many analysts cover GMAB?

13 analysts cover GMAB. Their consensus on GMAB is Buy, across those 13.

GMAB price $51.37 —

Insights · Forecast · Financials · Learn

Stocklytics home · Screener